Experimentica Ltd

Name: Experimentica Ltd
Address: MicroKatu 1, Kuopio, 70211, FI
Telephone: +358409307087

Koti
Suomi
Kuopio
Experimentica Ltd

Advancing Ophthalmic Drug Discovery Contract Research Organization

06/12/2023

Don't miss out on the opportunity to learn about our preclinical ocular drug development programs! Join us at our last meeting of 2023 at BioFIT in Marseille, France.

Experimentica's Chief Business Officer, Guillaume Demarne, will be there - playing at home - to discuss how our team and our in vitro and in vivo preclinical ocular models can support the development of your drug candidates.

Not attending BioFIT? No worries. Book a Teams meeting here:
https://bit.ly/HelpMeExperimentica

Subscribe to Experimentica’s newsletter:
http://bit.ly/Experimentica-NL

www.experimentica.com

10/11/2023

[PRESENTATION] Animal Models for Dry AMD Therapeutic Development | 4th Dry AMD Drug Development Summit | Boston, Nov 14-17, 2023

Jeffrey Jamison, Experimentica’s Chief Development Officer, will share his take on relevant in vivo models used to develop new drugs against dry AMD.

Focus:
- Differences between commonly used models of dry AMD
- Experimentica’s recently validated laser-induced geographic atrophy model

Find out more about the presentation and the full program of the event:
bit.ly/DryAMDmodels

Not attending the conference? Schedule a Teams meeting with us:
bit.ly/HelpMeExperimentica

07/11/2023

[SAVE THE DATE] Join us at 4th Dry AMD Drug Development Summit in Boston, MA, from November 14-17, 2023

Stay tuned - and don't miss out our featured presentation by Experimentica's Chief Development Officer Dr. Jeff Jamison.

Get all the details about the event at
https://dry-amd-therapeutics.com/

If you are unable to attend the conference, you can still schedule a Teams meeting with us by visiting
bit.ly/HelpMeExperimentica

03/11/2023

Experimentica invites you to meet at Bio-Europe 2023 in Munich on Nov 7-8, 2023, where you can learn about our preclinical ocular models and services.

Dr. Marc Cerrada-Gimenez, Experimentica's Chief Technology Officer, will be in attendance, providing a perfect opportunity to gain insights into our internal R&D and AI advancements, as well as our innovative imaging readouts.

Discover how our expertise in ocular in vitro and in vivo models can support the development your drug candidates.

If you are unable to attend Bio-Europe, don't worry. You can book a Teams meeting with us in the coming days:
https://bit.ly/HelpMeExperimentica

Subscribe to Experimentica's newsletter to stay updated on our latest developments.
http://bit.ly/Experimentica-NL

www.experimentica.com

01/11/2023

We are excited to announce our participation in Eyecelerator @ AAO 2023, a conference taking place in San Francisco, CA on November 2, 2023.

Join us at this event to connect with Experimentica’s CEO, Giedrius Kalesnykas, CBO, Guillaume Demarne, and CDO, Jeff Jamison. We will be discussing your preclinical drug development programs for ocular treatments.

For more information about the conference, visit the official website at https://www.eyecelerator.com/.

If you are unable to attend the conference, you can schedule a Teams meeting with us using this link:
bit.ly/HelpMeExperimentica.

Don't miss out on this opportunity to collaborate with Experimentica. Join us at Eyecelerator @ AAO 2023!

www.experimentica.com

26/09/2023

[CONFERENCE] Meet the team at the 4th Annual Gene Therapy for Ophthalmic Disorders conference in Boston on October 4-5, 2023!

Experimentica’s Chief Business Officer Guillaume Demarne and Chief Development Officer Jeff Jamison will attend the conference organized by HansonWade.

This is the perfect opportunity to discuss your ocular gene therapy programs and Experimentica’s expertise in routes of administration, imaging read-outs, tissue collection, immunohistochemistry, and qPCR, ELISA, and Western Blot capabilities.

Not attending the conference? Schedule a Teams meeting with them:
bit.ly/HelpMeExperimentica

20/09/2023

[POSTER] “Effect of Pertussis toxin and CFA on Meibomian gland function and secretion”. Marianna Bacellar-Galdino, DVM, PhD, will present at ACVO's Conference.

Experimentica’s Director of Veterinary Ophthalmology will attend ACVO's 54th Annual Scientific Conference in Boston on September 20-23, 2023. Marianna’s poster will showcase our Meibomian gland dysfunction (MGD) model in rabbits.

Find out more about the poster:
bit.ly/Experimentica-ACVO2023-Poster

Interested in the poster and the rabbit MGD model? Schedule an online meeting with us:
bit.ly/Experimentica-ACVO2023

The American College of Veterinary Ophthalmologists (ACVO) promotes excellence in veterinary ophthalmology through advanced training, certification, research and education.

15/09/2023

[CONFERENCE] Experimentica’s Director of Veterinary Ophthalmology will attend ACVO's 54th Annual Scientific Conference in Boston on September 20-23, 2023.

Stay tuned: Marianna Bacellar-Galdino, DVM, PhD, will present a poster showcasing Experimentica’s Meibomian gland dysfunction (MGD) model in rabbits.

Find out more about the conference program:
www.acvoconference.org/schedule

Not attending the conference? Schedule an online meeting with us:
bit.ly/HelpMeExperimentica

The American College of Veterinary Ophthalmologists (ACVO) promotes excellence in veterinary ophthalmology through advanced training, certification, research and education.

13/09/2023

[CONFERENCE] Our team is gearing up for Life Sciences Baltics 2023! Meet us in Vilnius and discuss how we can support your preclinical studies in Ophthalmology.

Meet with Guillaume Demarne, Experimentica’s Chief Business Officer, to discuss your ocular drug development programs.

The leading life sciences event in the Baltics brings together top decision-makers and the next generation of founders and talents from the Baltics and around the world.

Not attending the conference? Schedule a Teams meeting with Guillaume:
bit.ly/HelpMeExperimentica

05/05/2023

[EVENT] Experimentica Science Day - Pharmaceutical Drug Delivery: Lessons from Ophthalmology | May 26, 2023, Vilnius, LT.

Join us in Vilnius, Lithuania for a day of scientific exploration at the upcoming Experimentica Science Day - Pharmaceutical Drug Delivery: Lessons from Ophthalmology!

This event brings together leading university professors and industry experts in preclinical Ophthalmology to share insights and discoveries about ocular pathophysiology and animal models. Don't miss this opportunity to connect and learn from the best in the field.

Programme and free Registration
https://bit.ly/3pbERIy

Venue:
Martynas Mažvydas National Library of Lithuania
Gediminas av. 51, Vilnius, 3rd floor, 305 audience

20/04/2023

[ABSTRACT] Recombinant human PRG4 alleviates signs of allergic conjunctivitis in vivo.

Time and location to be announced

Authors: Iqbal S, De Alba M, Sagalov A, Hariani HN, Pappenhagen N, Ghosh AK, Rao VR, Fareed J, Bacellar-Galdino M, Kaja S

Purpose: Allergic conjunctivitis (AC) is a multifactorial disease associated with redness and swelling of the conjunctiva, increased lacrimation, and severe itching. Management includes lubricants, topical corticosteroids, NSAIDs, and antihistamines. Limited efficacy and drug-induced adverse reactions call for novel safer and more efficacious treatments. Lubricin/PRG4 is an endogenous proteoglycan that has emerged as a key natural molecule in the lubrication of the ocular surface. Compound 48/80 (C48/80) promotes mast cell degranulation and topical instillation of C48/80 is a well-established model for AC in rabbits. The purpose of this study was to investigate the efficacy of PRG4 in models for C48/80-induced AC.

All Experimentica ARVO 2023 abstracts:
http://bit.ly/3Kpew0i

19/04/2023

[ABSTRACT] Subconjunctival administration of Aflibercept protects against neovascularization in the mouse CNV model.

AMD anti-VEGF | 3:15 PM – 5:00 PM CDT on Monday, April 24 | C0186

Authors: Cerrada-Gimenez M, Vähätupa M, Lappeteläinen B, Tähtivaara L, Jokinen V, Haapaniemi A M, Vergun O, Kvietkauskiene N, Bijeikis S, Jarutis J, Kolehmainen A, Mertano P, Sarkola E, Kalesnykas G, Kaja S

Purpose: Anti-VEGF treatments have shown effectivity in limiting the progression of the neovascular lesions and improved disease outcome in the CNV model. Aflibercept has been approved since 2011 as treatment against AMD. Aflibercept is administered intravitreally every two months. In the current study we compared the efficacy of Aflibercept administered intravitreally and subconjuctivally in the mouse CNV model.

All Experimentica ARVO 2023 abstracts:
http://bit.ly/3Kpew0i

Osoite

MicroKatu 1
Kuopio
70211

Puhelin

+358409307087

Nettisivu

http://experimentica.com/contacts

Hälytykset

Tiedä ensimmäisenä ja anna meille oikeus lähettää sinulle sähköpostitse uutisia ja promootioita Experimentica Ltd :ltä. Sähköpostiosoitettasi ei käytetä muihin tarkoituksiin, ja voit perua milloin tahansa.

Ota Yhteyttä Yritys

Lähetä viesti Experimentica Ltd :lle:

Oikopolut

Oma Yritys listan huipulle Insinööritoimisto Kuopio :ssa?

Jaa

Kategoria

Biotekniikkayritys